When they work well, strategic partnerships merge the discovery-driven culture of the university with the innovation-driven environment of biotechs. But to make the chemistry work, each side must overcome the cultural and communications divide that tends to impair industry-university partnerships of all types and undercut their potential.
Expand your opportunities in commercializing university technologies and enhance your relationships with university technology transfer offices by registering today for this 90-minute webinar in which moderator Marie Powers of BioWorld Today will facilitate a discussion between Edward Lanphier, President and CEO, Sangamo BioSciences, Inc. and David Tiemeier, Senior Director, INVO (Innovation and New Ventures Office) at Northwestern University. During this interactive exchange each participant will share his thoughts and real-life experience on the design of a successful deal for intellectual property involving life science discoveries along with the opportunities and challenges these strategic partnerships represent.
Key Learning Points:
What are the key opportunities?
- How to establish and nurture relationships on both sides of the table
- How to build value and de-risk emerging technologies
- How to improve the reproducibility hit rate
What are the key challenges?
- How to develop rational start-up operational structures
- How to identify potential partners
- How to market technologies to potential partners
- How to develop internal or attract external funding to move university technologies across the Valley of Death
- The role of preclinical and other studies in building value for a technology
What are the terms that make these deals work?
- Perception of Value
- Exclusive vs. Non-exclusive Rights
- Up-front Fees
- Equity
- Ongoing Research Funding
- Objectives/Interests of Inventors
- Milestones
- Royalties
Register today to learn how to capitalize on university technology transfer opportunities for your company.
Your Experts:
Edward Lanphier, the founder of Sangamo BioSciences, Inc., has served as President, Chief Executive Officer and as a member of the Board of Directors since Sangamo's inception in 1995. Mr. Lanphier has over twenty-five years of experience in the pharmaceutical and biotechnology industry. From June 1992 to May 1997, he held various positions at Somatix Therapy Corporation, a gene therapy company, including Executive Vice President, Commercial Development and Chief Financial Officer. Prior to Somatix, he was President and Chief Executive Officer of BioGrowth, Inc., a biotechnology company that merged with Celtrix Laboratories to form Celtrix Pharmaceuticals, Inc. in 1991. From 1986 to 1987, he served as Vice President of Corporate Development at Biotherapeutics, Inc. From 1984 to 1986 Mr. Lanphier served as Vice President of Corporate Development at Synergen Inc. Prior to Synergen, he was employed by Eli Lilly and Company, a pharmaceutical company, in the strategic business planning biotechnology group. He currently serves on the board of directors of the Biotechnology Institute. Mr. Lanphier holds a B.A. in biochemistry from Knox College.
David Tiemeier joined INVO as Senior Director in July 2012. He leads a team that is responsible for building relationships with faculty, for helping to shape and prosecute University intellectual property, and for commercial assessment and licensing of University inventions into existing and start-up companies. The team looks for ways to build value in early-stage projects and draws heavily on internal and external experts to catalyze the translation of basic science into innovative products and services.
Mr. Tiemeier brings over twenty-five years of industry experience to INVO including leadership positions in research and business development with Monsanto, Searle, Pharmacia and Pfizer. After retiring from Pfizer in 2004, he work with the biotech companies NeoPharm, Immtech, and Kalypsys before joining UChicagoTech, the University of Chicago’s Office of Technology and Intellectual Property, as Deputy Director in 2006.
Mr. Tiemeier holds a B.S. in Chemistry from the University of Notre Dame and a Ph.D. in Biochemistry from the University of California, Berkeley. He completed postdoctoral studies in Molecular Genetics at the National Institutes of Health and served on the faculty of the University of California, Irvine, Medical School for three years before joining Monsanto.
Marie Powers served as a contributing writer for BioWorld Today before joining the staff in 2011. With more than 20 years on the health care beat, Ms. Powers has contributed to a variety of industry publications, including ENT Today, Managed Care Contracting & Reimbursement Advisor, Orthopaedic Practice Management, Neurology Practice Management, Capitation Management Report, Capitation Rates & Data, Physician Profiling & Behavior Change Report, and Women's Health Center Management. She's also served as a Contributing Editor to Technology Transfer Tactics.
